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Abstract
We recently reported a case in which a 54-year-old male experienced maintenance insomnia, generalized anxiety and panic
symptoms associated with consumption of a ﬁsh oil supplement enriched in eicosapentaenoic acid (EPA). We report here
that the same patient has experienced identical but more severe symptoms in response to the use of the leukotriene
receptor antagonist montelukast, in accordance with other cases reported to the Food and Drug Administration. Since
omega-3 fatty acids like EPA are precursors for the biosynthesis of eicosanoids including leukotrienes, a common factor to
these psychiatric adverse events may be perturbations in this highly complex system of lipid inﬂammatory mediators.

INTRODUCTION
Montelukast (Singulair®, Merck & Co.) is a leukotriene receptor
inhibitor that speciﬁcally antagonizes the cysteinyl leukotriene
type 1 receptor (CysLTR1). Biological agonizts of the CysLTR1
include leukotrienes-C4, -D4 and -E4, which are released by
immune cells to mediate inﬂammation of airways, the nasal
mucosa and other tissues [1]. Thus, montelukast and another
CysLTR1 antagonist, zaﬁrlukast, are effective treatments for
asthma and allergic rhinitis [2]. The Food and Drug Administration
has received numerous reports of neuropsychiatric adverse
events associated with montelukast, including suicidality, depression, abnormal behavior, aggression, anxiety, insomnia, nightmares, and night terrors [3] and special attention has been
paid to these effects in pediatric populations [4, 5]. In this case
report, we describe a patient who experienced severe anxiety
and maintenance insomnia with panic symptoms temporally
correlated with a month-long trial of montelukast, prescribed

for mild asthma. This case is unique in that the patient had
previously experienced similar symptoms associated with consumption of a ﬁsh oil supplement enriched in the omega-3 fatty
acid eicosapentaenoic acid (EPA) [6]. That such disparate agents
caused similar psychiatric adverse events may shed light on
whether and how lipid inﬂammatory mediators could affect fear
circuits in the brain.

CASE REPORT
The patient is a 56-year-old male in very good health. He exercises regularly, primarily walking, running, and bicycling, and
has an excellent cardiovascular proﬁle with a body mass index
of 23. He is educated at the doctoral level and is medically literate. As reported previously [6], he was diagnosed with major
depressive disorder at age 42 and was treated with ﬂuoxetine,
omega-3 fatty acids and psychotherapy which were eventually
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effective, with the depression going into a yet-continuing
remission starting at age 53. The patient had discontinued the
ﬂuoxetine more than 6 months after the depression had gone
into remission. Of note, he had not experienced signiﬁcant anxiety symptoms until age 54, which at that time were associated
with the use of EPA-enriched ﬁsh oil supplements. The patient
had taken the same reﬁned ﬁsh oil supplements for over 5 years
and he partially attributes the remission of his depression to
them, but they gradually began causing the anxiety and insomnia symptoms, which became noticeable by age 54 and abated
when he temporarily stopped taking the ﬁsh oil supplements.
A subsequent challenge with the ﬁsh oil triggered the symptoms again, so the patient stopped taking them altogether after
which the anxiety and insomnia symptoms were largely eliminated [6]. He was prescribed lorazepam for the anxiety symptoms, which by agreement was restricted to no more than
12 1 mg tabs per 6 months to prevent dependence.
During a recent annual physical exam, his primary care
practitioner suggested montelukast for his mild chronic asthma. Two to three weeks after initiating montelukast at 10 mg/
day he noticed gradually worsening generalized anxiety and
began waking suddenly after several hours of sleep. During his
awakenings, he often experienced strong sympathetic activation, with increased heart rate, ﬂushing and a loosening sensation in his viscera. These panic symptoms were associated
with ruminative thoughts in which routine life concerns led to
the imagination of catastrophic outcomes for himself, his family and society at large. He described one night in which he
experienced nasal congestion and had persistent, intrusive
fears of suffocation should his mouth somehow be forced shut.
He is experienced in somatic quieting and cognitive selfsoothing [7] but found these difﬁcult to execute in these nighttime panic episodes. Instead, he chose to get out of bed and
read until he was calm enough to resume sleep. On a few occasions he took 0.25–0.5 mg of lorazepam, often with a glass of
wine. The only other medications the patient used were ﬂuticasone 100 mcg-salmeterol 50 mcg inhalation powder (Advair®,
GlaxoSmithKline) and albuterol HFA, both for occasional asthma exacerbations. The anxiety symptoms occurred virtually
every night by the fourth week of taking montelukast.
The patient reported that in the daytime he was also frequently overcome by morbid fears of such things as aging in loneliness, his children failing at life or worldwide economic collapse.
At other times he would suddenly feel extreme anxiety about
expectations of him at his workplace, in which he experienced
a wave of sympathetic arousal, mainly felt as ﬂushing and an
increased heart rate. Because of the night-time awakenings he
was chronically sleep-deprived during this period, to which, based
on experience, he attributed the fact that he felt restless and ‘jittery,’ and had a pounding heart throughout much of the day. The
patient recognized that the current symptoms were very similar
to those associated with ﬁsh oil supplements, but he considered
them signiﬁcantly more intense than the previous episode.
The patient did not associate his anxiety symptoms with
the new medication until it was time to reﬁll his prescription.
He researched the adverse events associated with montelukast
and immediately decided to discontinue the drug after ~1
month of daily use. The panic symptoms during night-time
awakenings abated within a few days, while the awakenings
themselves and the general anxiety took a few weeks to largely
resolve. Several months after the discontinuation of montelukast the patient reported that he felt a ‘normal’ mild degree of
daytime anxiety and experienced mild maintenance insomnia
less than once a week with no panic symptoms.

DISCUSSION
Post-marketing vigilance has resulted in the collection of many
reports of neuropsychiatric adverse events associated with
montelukast, particularly in the FDA Adverse Event Reporting
System (FAERS) database [3, 4, 8]. The most frequently reported
neuropsychiatric adverse events with ‘serious outcomes’ in the
FAERS database were suicidal ideation, depression, aggression,
abnormal behavior, anxiety and insomnia. However, there have
been few speciﬁc, detailed reports of such adverse events in the
literature [9, 10]. The current report is unique in the extended
history of the patient and his medical literacy—he lectures on
psychiatric medicines in both a Doctor of Pharmacy program
and a graduate counseling psychology program—as well as the
close temporal correlation of the use of montelukast with his
anxiety symptoms. The reaction to montelukast described in
this report is strikingly similar to a previous incident in the
same patient 18 months earlier, in which the symptoms of daytime anxiety and maintenance insomnia with night-time panic
symptoms were evoked by the consumption of 2 g/day highEPA ﬁsh oil supplements [6]. The symptoms provoked by both
the ﬁsh oil and montelukast were much more intense than
what had become the moderate background level of anxiety
symptoms for the patient at age 56. Because, the intense
anxiety symptoms occurred only in conjunction with consumption of the two agents and were qualitatively very different from any previous symptoms experienced by this
patient, it is unlikely that the episode described here was a
coincidental exacerbation in the natural history of his psychological health.
In this patient, two disparate manipulations of the eicosanoid signaling system had very similar effects on the expression of fear and worry behaviors. EPA is a metabolic precursor
to many eicosanoids and leukotrienes, and the reaction of the
global eicosanoid/leukotriene signaling system to an exogenous
increase in EPA is likely to be quite complex and variable
between individuals and possibly within individuals over time [11].
In addition, blockade of the CysLTR1 by montelukast may
have wider effects on this system beyond the prevention of
leukotrienes-C4, -D4 and -E4 from promoting inﬂammation.
Interestingly, expression of a key protein regulating eicosanoid
metabolism was strongly correlated with anxiety-like behavior
in mice [12]. Since montelukast and ﬁsh oil are widely used
agents and the vast majority of patients who use them experience no neuropsychiatric side effects, the subject of the current
report may have an uncommon or idiosyncratic physiological
reaction to these agents. His response to high-EPA ﬁsh oil
changed in his early ﬁfties from apparently beneﬁcial to demonstrably aversive, which may simply be associated with normal aging, as manifested perhaps by reduced testosterone.
Clinicians treating both respiratory and psychiatric disorders
should be aware of possible idiosyncratic adverse events
related to the use of medicines that affect the lipid inﬂammatory signaling system. More research is needed into the effects
of this system on the amygdalae and other neural elements
mediating fear.
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